Eli Lilly’s Weekly Insulin Outperforms Daily Counterparts in Phase III Trials

Eli Lilly has achieved significant strides in diabetes care with its weekly insulin injection, efsitora alfa. Recent Phase III trials reveal promising outcomes, posing as a likely competition to Novo Nordisk, which faced a setback with its basal insulin, icodec. The findings could mark a significant shift in diabetes treatment, influencing patient compliance and overall care.

The phase 1 and phase 3 trials provided the backdrop for these ground-breaking results. Phase 1 focused on patients new to insulin, showing that efsitora alfa lowered A1C by 1.31% in a 52 week period, slightly edging out daily insulin 1.27% reduction. In phase 3, targeting type 2 diabetes patients transitioning from daily insulin, Eli Lilly’s weekly insulin again displayed superior performance with a 0.86% reduction in A1C levels at 26 weeks compared to 0.75% for daily.

Beyond efficacy, efsitora alfa’s safety profile mirrored that of daily insulin treatments, with comparable rates of severe glucose deficient events. Notably, patients on weekly injections experienced similar time-in-range outcomes, an important metric for diabetes management. “Weekly insulins like efsitora have the potential to transform diabetes care, making it easier and more convenient for patients to initiate insulin therapy,” stated Lilly’s senior vice president of product development.

With detailed results and analyses soon to be published, Lilly’s efsitora alfa is expected to redefine diabetes treatment, enhancing patient convenience and compliance. This advancement may provide Lilly with a competitive edge over competitors, setting the stage for a new era in diabetes care.